MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

BMS-986142

CAS No. : 1643368-58-4

MCE 国际站：BMS-986142

产品活性：BMS-986142 是一种有效的、具有高选择性的 Bruton's 酪氨酸激酶 (BTK) 可逆性抑制剂，其 IC₅₀值为 0.5 nM。

研究领域：Protein Tyrosine Kinase/RTK

作用靶点：Btk

In Vitro: BMS-986142 potently inhibits human recombinant BTK with an IC₅₀ of 0.5 nM in enzymatic assays. Against a panel of 384 kinases, BMS-986142 is highly selective, with only five other kinases (Tec, ITK, BLK, Txk, BMX) inhibited with <100-fold selectivity for BTK. Four of these kinases are Tec family kinases, of which BTK is a member, and only Tec (IC₅₀=10 nM) is inhibited with <30-fold selectivity compared with BTK. BMS-986142 does not inhibit CD40L-induced expression of CD86 or CD69 on peripheral blood B cells (IC₅₀>10,000 nM for both). When Ramos B cells are treated with anti-IgM to activate BCR, BMS-986142 inhibits BTK-dependent calcium flux with an IC₅₀ of 9 nM.

In Vivo: BMS-986142 at 4, 10, and 30 mg/kg results in dose-dependent reductions of 26%, 43%, and 79% in clinically evident disease, respectively, at the end of the study. Interestingly, 4 mg/kg BMS-986142 provides an additive benefit in clinical scores (54% inhibition) when co-administered with MTX versus 19% inhibition with MTX alone. Co-administration of BMS-986142 at 4 mg/kg with MTX result in a 53% reduction in inflammation and bone resorption compared with 24% and 10%, respectively, with either drug alone. Furthermore, serum anti-collagen II IgG titers are significantly inhibited with 10 and 30 mg/kg BMS-986142. BMS-986142 also produces dose-dependent reductions in clinical scores when administration is delayed until the collagen booster on day 21. BMS-986142 doses of 2, 4, and 25 mg/kg in this therapeutic dosing regimen result in clinical score reductions of 17%, 37%, and 67%, respectively, at the end of the study.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Atuzabrutinib  |  PCI 29732  |  JAK3/BTK-IN-6  |  Pirtobrutinib  |  CNX-500  |  BTK inhibitor 17  |  Remibrutinib  |  RN486  |  GDC-0834 Racemate  |  Spebrutinib besylate  |  BTK inhibitor 19  |  BMX-IN-1  |  BMS-935177  |  Ibrutinib  |  PF-06250112  |  QL-X-138  |  SJF620 hydrochloride  |  PROTAC BTK Degrader-2  |  BTK-IN-8  |  JAK3/BTK-IN-3  |  JS25  |  JAK3/BTK-IN-2  |  (R)-Zanubrutinib  |  Edralbrutinib  |  Branebrutinib  |  Poseltinib  |  BTK inhibitor 20  |  RET-IN-14  |  QL47  |  BTK-IN-23

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

货号: HY-101856

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。